Hyperparathyroidism of Renal Disease
Author(s) -
Noah K Yuen,
Shubha Ananthakrishnan,
Michael J. Campbell
Publication year - 2016
Publication title -
the permanente journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.445
H-Index - 30
eISSN - 1552-5775
pISSN - 1552-5767
DOI - 10.7812/tpp/15-127
Subject(s) - medicine , calcimimetic , parathyroidectomy , kidney disease , secondary hyperparathyroidism , parathyroid hormone , vitamin d and neurology , hyperparathyroidism , cinacalcet , disease , urology , renal function , endocrinology , calcium
Renal hyperparathyroidism (rHPT) is a common complication of chronic kidney disease characterized by elevated parathyroid hormone levels secondary to derangements in the homeostasis of calcium, phosphate, and vitamin D. Patients with rHPT experience increased rates of cardiovascular problems and bone disease. The Kidney Disease: Improving Global Outcomes guidelines recommend that screening and management of rHPT be initiated for all patients with chronic kidney disease stage 3 (estimated glomerular filtration rate, < 60 mL/min/1.73 m(2)). Since the 1990s, improving medical management with vitamin D analogs, phosphate binders, and calcimimetic drugs has expanded the treatment options for patients with rHPT, but some patients still require a parathyroidectomy to mitigate the sequelae of this challenging disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom